Amneal and Zambon Biotech enter agreement for Parkinson’s treatment
Betsy Goodfellow | February 28, 2024 | News story | Research and Development | Amneal pharmaceuticals, Neurology, Parkinson's disease, Zambon Biotech, licensing agreement
Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the EU, UK and Switzerland.
The drug is a novel, oral formulation of carbidopa/levodopa (CD/LD) in extended release capsules, intended for the treatment of Parkinson’s disease currently under review by the US Food and Drug Administration (FDA). It is expected that Zambon will seek regulatory approval and commercialise the drug in Europe.
Financial terms of the agreement have not been disclosed.
Chirag and Chintu Patel, co-chief executive officers at Amneal, commented: “We believe IPX203 can improve the lives of the more than ten million people worldwide living with Parkinson’s disease. It has been a strategic goal of Amneal to ensure that not only US patients, but also Parkinson’s patients worldwide have access to our products. Zambon, a family-owned business with whom we share a long-term vision and commitment toward patient communities, is the right partner to extend the reach of IPX203 to Europe.”
Frank Weber, chief executive officer at Zambon Biotech, added: “Zambon Biotech’s mission is to build a long-term pipeline of innovative medicines that make patients’ lives better. Given our group’s capabilities in commercialisation and our existing footprint in neurology, particularly Parkinson’s, we are pleased to partner with Amneal to bring IPX203 to Parkinson’s patients in Europe.”
Betsy Goodfellow
Related Content
EVerZom enters research and licensing agreement with GENFIT
EVerZom, a French biotech company developing exosome-based therapies for regenerative medicine, has entered into a …
Roche advances treatment for Parkinson’s disease
Swiss biopharma, Roche, has announced its decision to proceed with phase 3 trials of prasinezumab, …
Abbvie acquires Cerevel Therapeutics
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple …
